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Case definitions for European Lyme disease have been 
published. However, multiple erythema migrans may 
pose a diagnostic challenge. Therefore, we retrospecti-
vely reviewed the clinical and serological findings and 
response to therapy in a cohort of consecutive 54 patients 
with PCR-confirmed erythema migrans, referred to a 
university dermatology clinic. The proportion of patients 
with multiple erythema migrans lesions (usually 2 or 3) 
was almost equal (46%) to the proportion of patients 
with single erythema migrans lesions (54%). All patients, 
except for 2 multiple erythema migrans patients with a 
concomitant autoimmune disease, completely responded 
to treatment. In conclusion, multiple erythema migrans 
may be more common than anticipated, and since only 
50% of the patients were seropositive when seeking medi-
cal help, PCR testing of skin lesions is helpful to confirm 
the diagnosis in clinically atypical cases. Key words: Lyme 
borreliosis; Lyme disease; erythema migrans; multiple ery­
thema migrans; Borrelia burgdorferi.
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In Europe, Lyme borreliosis (LB) displays the highest 
incidence in the north and central parts of Europe 
(Austria, Germany, Slovenia, Baltic states, Sweden and 
Finland) (1, 2).
Approximately 1,500 laboratory-confirmed LB infec-
tions are diagnosed annually in Finland according to the 
National Institute for Health and Welfare (3), but this 
number is an underestimate, since many patients with 
erythema migrans (EM) are treated on clinical grounds 
with no laboratory confirmation.
Almost 80% of all patients with LB due to Borrelia 
burgdorferi sensu lato have cutaneous skin lesions (4). 
The clinical hallmark lesion of early LB is EM, but 
multiple EM (MEM) lesions are also frequently seen 
in European patients (5–8). MEM can be an early sign 
of disseminated LB (5, 9). Early recognition of such 
manifestations is important in order to avoid evolu-
tion to systemic manifestations, such as neurological, 
ophthalmological, cardiac or rheumatic borreliosis. In 
addition, lymphocytoma can be caused by B. burgdor-
feri. Acrodermatitis chronica atrophicans (ACA) is a 
late skin manifestation of LB (10). Common systemic 
symptoms associated with skin manifestations of LB 
are typically arthralgia, muscle pain, fatigue, headache, 
fever, and nausea.
Recently, new case definitions for European LB have 
been published (2). However, the highly variable clinical 
manifestations of MEM may pose a clinical challenge 
and often need diagnostic support from laboratory tests. 
We performed a retrospective review of a cohort of 
patients with LB with solitary or multiple EM confirmed 
with PCR-based detection of B. burgdorferi in skin 
lesions. We analysed the demographics and clinical 
presentation, with a special emphasis on the presence 
of systemic symptoms and serological response during 




We reviewed the data of all patients with PCR-confirmed B. 
burgdorferi infection seen at the Department of Dermatology 
at Helsinki University Central Hospital from 2008 to 2010. 
During this period, a total of 87 patients were PCR-positive 
for B. burgdorferi in the skin biopsy. Only those with solitary 
EM (SEM) and MEM were included in this study, this group 
consisted of 54 patients. Demographic data, clinical features, 
photographs, serology, and skin lesion histology were retrieved 
from patient files. Antibiotic therapy, dosage and length of 
treatment were reviewed, in addition to therapeutic outcome. 
Borrelia antibodies
Anti-borrelial immunoglobulin (Ig)G and IgM antibodies 
were determined by 2 immunoassays. The screening test was 
based on an enzyme immunoassay using B. afzelii whole-cell 
lysate (strain PKo) as an antigen in the determination of IgM 
antibodies. In IgG antibody determinations, a variable surface 
antigen, VlsE (variable major protein-like sequence expressed) 
antigen from B. afzelii (strain PKo) was added (Genzyme Viro-
tech GmbH, Russelsheim, Germany). For all positive screening 
tests, a confirming chemiluminescent immunoassay (Liaison®) 
was performed as a routine procedure using recombinant VlsE 
antigen obtained from B. garinii (PBi strain) for IgG antibodies 
and recombinant VlsE antigen combined with OspC (outer sur-
face protein C) obtained from B. afzelii (PKo strain) for IgM 
antibodies (Diasorin, Saluggia, Italy) by HUSLAB (11). In the 
screening test, the cut-off for antibody positivity was titre level 
9 (Virotech units), where 9–11 was borderline and > 11 was a 
positive result. In the confirming test, the cut-off was at titre 
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level 10 for IgG and 18 for IgM antibodies (10–15 was border-
line for IgG and > 15 was positive; 18–22 was borderline for 
IgM and > 22 was positive). The antibody result was considered 
positive if IgG antibodies against VlsE were positive. If only 
IgM antibodies were slightly positive or the antibody titres were 
at the borderline level, the result was considered borderline. 
If the IgG and IgM antibodies were both at negative level, the 
result was considered negative.
PCR-based detection of B. burgdorferi skin lesions
A skin biopsy was obtained from the active margin area (ery-
thema) of suspected lesions, snap frozen and stored at –70ºC. 
The DNA was extracted as previously described (12) and the 
radioactive OspA-specific probe originally used for hybridi-
zation confirmation, has been replaced with a non-isotopic 
label, digoxigenin (12). In addition to the OspA gene, the PCR 
amplification also covered the 23S and 16S ribosomal RNA 
genes (primer sequences and annealing temperatures provided 
on request). All amplifications were carried out with a MJ 
Research PTC-200 thermal cycler. After PCR, samples were 
analysed on a 1.5% agarose gel, the amplicons were transferred 
to nylon membranes and hybridized with the relevant probe, 
immunodetected with anti-digoxigenin-conjugated alkaline 
phosphatase (Roche Applied Science, Mannheim, Germany) 
and visualized with the chemiluminescence substrate CSPD 
(Boehringer Mannheim, Mannheim, Germany) on X-ray films. 
Histopathology
Histopathological analysis was performed as a part of routine 
diagnostics in the Dermatopathology Laboratory of Helsinki 
University Central Hospital by an experienced dermatopatho-
logist. Typically, in EM the epidermis is normal, but an inflam-
matory cell infiltrate consisting of lymphocytes and plasma cells 
is seen in the dermis around vessels and between the collagen 
bundles. The inflammatory cell infiltrate can be sparse or mo-
derate and sometimes even extends to the subcutis.
Therapy
According to the recently updated evidence-based national 
guidelines for diagnosis and treatment of cutaneous bacterial 
infections (13), treatment of SEM and lymphocytoma is recom-
mended via oral amoxicillin 500–1,000 mg 3 times a day or oral 
doxycycline 100–150 mg twice a day for 2–3 weeks. ACA and 
MEM are usually treated with ceftriaxone 2 g intravenously 
daily for 3 weeks (14), which is consistent with the guidelines 
of the European Concerted Action on Lyme Borreliosis (EU-
CALB). ACA and MEM can also be treated as recommended 
by EUCALB (15). Table I shows the general treatment recom-
mendations used in Finland.
Statistical analysis
Data were analysed using SPSS (version 19.0.0.1; IBM SPSS 
Inc., Chicago, IL, USA) and Microsoft Excel 2003 (Microsoft, 
USA) software. The determination of the p-values was based 
on Fisher’s exact test and Pearson χ2.
RESULTS
The mean age of the patients was 53 years (age range 
15–84 years) and most of the patients were female. 
Table II shows the demographic data of the patients in 
this study. Importantly, only 24% (13/54) of patients 
in our study recalled having a tick bite. No statistical 
difference in recalling a tick bite was found between 
patients with SEM (8/28%) and those with MEM 
(5/20%; p = 0.545).
Variation in the clinical presentation of SEM and MEM 
lesions and frequency of associated symptoms
Among the 54 consecutive patients, 29 presented with 
SEM (54%) and 25 with MEM (46%). Most of the pa-
tients with MEM lesions had only 2 or 3 lesions (13/25; 
52%). The highest number of recorded MEM lesions 
was 10 lesions in one patient. The size of the skin lesions 
varied, with the widest skin lesions 20–50 cm in diameter. 
Table I. General treatment recommendations of cutaneous Lyme 
borreliosis in Finland. The treatment of solitary erythema migrans 
(EM) and lymphocytoma is based on the evidence-based Finnish 
guidelines for diagnosis and treatment of cutaneous bacterial 
infections (13). In Finland acrodermatitis chronica atrophicans 
(ACA) and multiple EM (MEM) are usually treated with ceftriaxone 
(15) while amoxicillin is used for MEM in case ceftriaxone is 
contraindicated (14). ACA and MEM can also be treated with 
peroral antibiotics according to the European Concerted Action 
on Lyme Borreliosis (15)
Skin lesion type Medication Dosage Course, days
Erythema migrans Amoxicillina 500–1,000 mg ×3 14–21
Doxycyclinea 100–150 mg ×2 14–21
Lymphocytoma Amoxicillina 500–1,000 mg ×3 14–21
Doxycyclinea 100–150 mg ×2 14–21
Multiple erythema 
migrans
Ceftriaxonea 2000 mg ×1 (i.v.) 14–21
Amoxicillin 500–1,000 mg ×3 14–30
Doxycyclinea 100–150 mg ×2 14–30
Acrodermatitis 
chronica atrophicans
Ceftriaxonea 2000 mg ×1 (i.v.) 21
Amoxicillin 500–1,000 mg × 3 14–30
Doxycyclinea 100–150 mg ×2 14–30
aConsistent with the guidelines of the EUCALB (15).
Table II. Selected characteristics of 54 patients with PCR-confirmed 
solitary or multiple erythema migrans
Patients
Male, n (%) 18 (33)
Female, n (%) 36 (67)
Age, years, mean (median) [range] 53 (56) [15–84]
Tick bite recalled 13 (24)
Erythema migrans
Total number of patients with SEM–/SEM+ 29 (54)
Patients with SEM– 21 (72)
Patients with SEM+ 8 (28)
Total number of patients with MEM–/MEM+a 25 (46)
Patients with MEM– 16 (64)
Patients with MEM+ 9 (36)
Patients with annular erythemas 25 (46)
Patients with homogeneous erythemas 18 (33)
Patients with diffuse light erythema 4 (7)
Patients with undefined typeb of erythema 7 (13)
aRange 2–10 lesions. bNo photographs available, no detailed description of 
the clinical appearance in the patient files.
SEM–: solitary erythema migrans without associated systemic symptoms; 
SEM+: solitary erythema migrans with associated systemic symptoms; 
MEM–: multiple erythema migrans without associated systemic symptoms; 
MEM+: multiple erythema migrans with associated systemic symptoms.
Acta Derm Venereol 93
695Solitary and multiple erythema migrans
If the size was not mentioned in the files, the size was 
approximated on available photographs. As to the locali-
zation of the skin lesions, most patients (61%) presented 
with lesion(s) on the lower extremities (Table III). 
The skin lesions were either annular (25/47) or homo-
geneous (18/47) among the 47 cases photographed or 
recorded in detail (Fig. 1). Only a diffuse light erythema 
was reported in 4/47 patients. Light scaling, itch, clinical 
appearance reminding of other skin lesions (herpes zos-
ter-, erysipelas-, haematoma- or vasculitis-like lesions), 
absence of migration of the erythema, uneven borders of 
the erythema or atypical colour of the erythema(s) were 
considered as atypical symptoms of LB by the referring 
physicians. Typically, B. burgdorferi infection was not 
diagnosed in the primary healthcare, since the skin le-
sions had been present for varying periods of time and 
without an obvious preceding tick bite. Most patients 
(n = 29) were referred to the Department of Dermatology 
by primary healthcare physicians with the diagnosis 
“dermatitis non specificata”. Eleven of these 29 patients 
(38%) had received inadequate oral or local antimicro-
bials or topical steroids. The remaining 24 patients were 
suspected of having LB, and 21 of these patients were 
referred by their physicians for confirmatory tests and/or 
for treatment of LB. Two patients were referred by their 
physicians because of persisting LB skin lesions after 
adequate treatment. Six of the patients were referred from 
the Department of Infectious Diseases. 
The results of the routine histological examination 
before PCR-confirmation were typical for LB in 50/52 
(96%) patients (perivascular inflammatory cell infiltrate 
consisting of lymphocytes and plasma cells, occasio-
nally also between the collagen bundles). In one case 
septal panniculitis had developed below the site of EM 
and in another one the histology showed granuloma 
annulare.
In this cohort, 28% (8/29) of patients with SEM also 
had systemic symptoms, including headache, arthralgia, 
joint stiffness, fatigue, vertigo, fever, skin or muscle 
pain, visual disturbances, paraesthesia, muscle spasms, 
and sensations of arrhythmia. These symptoms were 
slightly more common among patients with MEM (9/25, 
36%), although this did not reach statistical significance 
(Fisher’s exact test p = 0.566). 
Borrelia serology is more often positive in MEM patients 
with systemic symptoms
Serological screening was performed, with certain 
exceptions, at the initial stage of presentation (in 48 
patients), immediately after treatment (in 25 patients), 
and during follow-up 6–24 months after treatment (in 
37 patients) (Fig. 2). IgG and IgM antibodies were 
determined with the screening test, and if positive, also 
with the confirmatory test. For SEM, serological testing 
was performed because of the atypical presentation 
and/or unusual delay of evolution, as recommended 
in recent guidelines (2).
Half of the patients (24/48; 50%), had positive se-
rology at the initial stage. The highest positivity of 
B. burgdorferi-specific antibodies at the initial stage 
was found in MEM patients with associated systemic 
symptoms (71.4%). Surprisingly, the initial serology 
was most often negative among MEM patients without 
associated systemic symptoms (6/14; 43%) (Table IV). 
However, no statistically significant difference was 
found in the frequency of the serological results at 
the initial stage (Pearson χ2 p = 0.440). After adequate 
antimicrobial therapy, the antibody titres tended to de-
crease, although 7 patients still had positive serology 
6–24 months after treatment (Fig. 2). Two of these pa-
tients had SEM and 5 had MEM. VlsE IgG-antibodies 
decreased by more than 50% in 6 of these 7 patients.
Comparable treatment responses in all patient groups
The antibiotic regimens used for patients with the dif-
ferent types of skin lesions are shown in Table V. As a 
result of antimicrobial treatment, 52 of 54 (96%) pa-
tients were cured of their skin lesions, 1/54 had partially 
persisting skin lesions, and 1/54 had persisting skin 
lesions for at least 17 months. The skin lesions were 
completely cured in all 29 patients with SEM. Slight 
hyperpigmentation remained in 2 SEM patients without 
associated systemic symptoms. Twenty-three of the 
25 (92%) patients with MEM were completely cured. 
Two patients with pre-existing autoimmune diseases 
(Table VI) experienced some skin symptoms even after 
the antibiotic treatment. Neither of these 2 patients had 
any systemic symptoms of LB. The first patient with 
partly persisting skin lesions had coeliac disease. She 
received treatment with doxycycline for 8 weeks. Her 
skin lesions persisted for 15 months post-treatment 
showing a lichenoid reaction histologically. 
The second patient presented with MEM-like skin 
lesions on the same location 17 months post-treatment 
and had concomitant Sjögren’s syndrome. He was 
treated with ceftriaxone for 3 weeks. PCR on the first 
skin biopsy, with lymphocytic infiltrates, was positive 
Table III. Locations of skin lesions in 54 patients with single or 
multiple erythema migrans













SEM– (21) 11 5 3 2
SEM+ (8) 5 3 0 0
MEM– (16) 11 12 7 0
MEM+ (9) 6 6 6 0
Total (54) 33 26 16 2
SEM–: solitary erythema migrans without associated systemic symptoms; 
SEM+: solitary erythema migrans with associated systemic symptoms; 
MEM–: multiple erythema migrans without associated systemic symptoms; 
MEM+: multiple erythema migrans with associated systemic symptoms.
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for 2 different B. burgdorferi genes, while a subsequent 
biopsy obtained 18 months later from a persisting skin 
lesion showed granuloma annulare histology and was 
weakly positive for the borrelia OspA gene only. Clini-
cally, his skin lesions had changed from homogeneous 
erythematous lesions to annular lesions post-treatment. 
Two years previously he had had a clinically success-
fully treated EM on his back. 
Fig. 1. Polymorphism of the clinical presentations of solitary erythema migrans (SEM) and multiple erythema migrans (MEM). The pictures are taken 
before antibiotic therapy unless stated otherwise. (A–C) Typical annular MEM lesions on several locations in a 53-year-old man. (D) MEM on the thigh of 
a 65-year-old woman. (E, F) MEM lesions on the thighs and buttocks of a 25-year-old woman. (G, H) MEM lesions on the upper arm and on the anterior 
upper thigh of a 43-year-old woman. (I) Erythematous patches of MEM on the legs in a 54-year old woman. (J, K) MEM lesions on the right ankle on 
a 40-year-old woman. (L) SEM on the back of a 64-year-old woman. The atypical clinical appearance might be a result of a preceding treatment with 
cephalexin. (M) SEM with somewhat lacy borders on the thigh of a 25-year-old woman. (N) The same skin area 2 years later, after amoxicillin therapy, 
with faint hyperpigmentation. (O) SEM of the right hand of a 54-year-old woman. Notice the oedema and redness on the distal part of the fingers and on 
the back of the right hand.
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Altogether, 17/54 (31%) patients reported associa-
ted systemic symptoms during follow-up. Six of the 8 
patients with associated systemic symptoms and SEM, 
were completely cured after antimicrobial therapy. The 
2 patients with partially persisting systemic symptoms 
were both treated with amoxicillin or doxycycline 
and with preceding or following ceftriaxone 2 g intra-
venously for 3 weeks. One of them still experienced 
vertigo after treatment, although neuroborreliosis was 
ruled out, and the other had occasional idiopathic muscle 
spasms (normal brain magnetic resonance). Among the 
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Fig. 2. (a) Serological positivity for Lyme 
borreliosis at different stages of treatment 
and follow-up. The number of patients with 
positive serological test result for Borrelia 
antibodies (the positivity was based on the final 
statement based on both IgG and IgM antibodies 
as described in the text) at 3 time-points in 
relation to treatment. Serological testing was 
performed at the initial stage (before treatment) 
in 48 patients, immediately after treatment in 
25 patients and 6–24 months after treatment 
in 37 patients. The number after the slash (/) 
indicates the number of tested patients in each 
subgroup. The patients are divided into groups 
according to type of skin lesion and presence 
or absence of associated systemic symptoms, 
such as arthralgia, fever and fatigue for example. 
(b) IgG and IgM antibody levels at various 
stages of the disease, and after treatment. The 
cut-off for antibody positivity in the screening 
tests (BorrAbG, BorrAbM) was at titre level 
9. In the confirming test, the cut-off was at 
titre level 10 for IgG (VlsEAbG) and 18 for 
IgM antibodies (VlsEAbM). SEM–: solitary 
erythema migrans without associated systemic 
symptoms; SEM+: solitary erythema migrans 
with associated systemic symptoms; MEM–: 
multiple erythema migrans without associated 
systemic symptoms; MEM+: multiple erythema 
migrans with associated systemic symptoms.




(n = 19) 
n (%)
SEM+ 
(n = 8) 
n (%)
MEM– 
(n = 14) 
n (%)
MEM+ 
(n = 7) 
n (%)
Total 
(n = 48) 
n (%)
Positive 8 (42.1) 5 (62.5) 6 (42.9) 5 (71.4) 24 (50.0)
Borderline 6 (31.6) 2 (25.0) 2 (14.3) 0 (0.0) 10 (20.8)
Negative 5 (26.3) 1 (12.5) 6 (42.9) 2 (28.6) 14 (29.2)
SEM–: solitary erythema migrans without associated systemic symptoms; 
SEM+: solitary erythema migrans with associated systemic symptoms; 
MEM–: multiple erythema migrans without associated systemic symptoms; 
MEM+: multiple erythema migrans with associated systemic symptoms.
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9 MEM patients with systemic symptoms, 5 were com-
pletely cured (from associated systemic symptoms), 4 
still reported fatigue, joint or muscular pain. One of the 
latter showed a significant decrease in antibody levels 
compared with the first measurement. The other 3 had 
only slightly elevated antibody levels and showed no 
significant change during follow-up.
DISCUSSION
This study on Nordic patients with MEM confirmed 
with PCR from skin biopsies is the largest of its kind. 
According to our results, MEM may be more frequent 
in Europe than previously thought. The most recent 
case definition paper (2) does not state MEM frequen-
cy. How ever, according to several central European 
studies, MEM is expected to occur in 4–40% of the 
patients with EM (5–7). In our cohort, we observed a 
higher rate of EM patients with multiple lesions 25/54 
(46%). One could ask whether the high prevalence of 
MEM in our cohort could be due to the assumption that 
MEM cases are more likely to be positive in the PCR 
confirmatory assay due to a higher number of microor-
ganisms expected in these patients. However, the PCR 
assay we use is extremely sensitive, previously shown 
to detect 0.01 pg of Borrelia DNA (12) and, thus, not 
a likely explanation for a bias. On the contrary, the 
relatively high frequency of MEM may rather reflect 
the fact that many patients with classical SEM are not 
referred to a dermatology clinic, while MEM patients 
are more readily referred because of differential diag-
nosis difficulties.
In this study, 50% of patients with SEM or MEM 
were seropositive at the initial stage. Twenty-five were 
re-tested immediately after treatment, and 68% tested 
positive, showing that in some initially-seronegative 
patients seroconversion occurs during antimicrobial 
treatment. Specifically, 19% of SEM and MEM patients 
were still seropositive 6–24 months after treatment. 
Comparable with our results, Philipp et al. (16) repor-
ted VlsE seropositivity in 51% (61/120) of American 
patients with solitary (41%, 38/93) or multiple (85%, 
23/27) EMs at the initial stage and a seropositivity of 
88% (105/120) during the convalescence period 1–8 
weeks after presentation. The rate of seropositivity then 
decreased to 41% during the 6–12 months of follow-up. 
Tjernberg et al. (17) studied seroreactivity to VlsE pro-
tein IR6 peptide variants and the synthetic C6 peptide in 
Swedish patients with SEM and found seropositivity in 
66% of cases at presentation, in 64% at 2–3 months and 
in 44% at 6 months follow-up. Thus, in our patients the 
seroreactivity more often turned negative during follow-
up. Differences in the seropositivity rates between the 
above-mentioned studies may be due to methodological 
differences, various criteria for positivity, timing of 
sampling or due to differences between European and 
American causative subspecies.
Thus far, no borrelia antigen has been shown to be 
superior to others in diagnostics of early LB. However, 
VlsE has been shown to be at least equally sensitive and 
specific compared with other borrelia antigens (18–21). 
It has even been suggested that 1-step tests with enzyme-
linked immunoassay (ELISA) using VlsE antigen could 
replace the 2-step approach using ELISA followed by a 
confirming western blot (18, 21). In this study we used 
VlsE as an antigen in the confirming ELISA tests and, 
thus, did not use immunoblots. In addition, the 2-step 
approach is recommended in other forms of LB, but not 
in SEM (22, 23).
Remarkably, only 11/21 MEM patients tested at the 
initial stage were seropositive. Thus, confirmatory 
PCR testing of the skin lesion is needed, in clinically 
doubtful cases. Determination of borrelia antibodies 
is not recommended in case of classical SEM, with 
or without systemic symptoms (2), but we emphasize 
the need for serology in case of atypical clinical EM, 
resistance to adequate antibiotic therapy or in case of 
multiple lesions. Based on our experience of 20 years of 
Table V. Treatment and treatment outcome of patients with solitary 
or multiple erythema migrans (SEM or MEM)





SEM (21) 12 Amoxicillin Cured
4 Doxycycline Cured









MEM (16) 4 Amoxicillin Cured
5 Doxycycline Cured: 4
Partially cured: 1
7 Ceftriaxone Cured: 6
Persisting: 1
MEM with associated 
systemic symptoms (9)
1 Amoxicillin Cured





Sixteen of the 22 patients who were treated with ceftriaxone also received 
treatments with amoxicillin and/or doxycycline. Eight of all of the patients 
had also previously been treated with inadequate antibiotics (cephalexin, 
cefuroxime) prior to diagnosis of Lyme borreliosis.








Patients without autoimmune disease 46 0 46
Patients with autoimmune disease 6 2 8
Total 52 2 54
Screening for autoimmune diseases was not performed. Only pre-existing 
autoimmune diseases were recorded from the patient files.
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B. burgdorferi PCR technology, we would recommend 
it as a useful additional diagnostic tool. However, the 
method shows B. burgdorferi DNA only, not replicating 
microbes, and the DNA might remain in the tissue even 
long after successful treatment (24).
Post-Lyme disease and persisting symptoms after 
adequate treatment has been the subject of many studies 
(7, 24–27). In our study, a complete clinical cure of the 
skin lesions was achieved in all patients with SEM. In 
MEM, a complete cure of the skin lesions was achieved 
in 92% of the patients. In some patients with properly 
treated EM a slight hyperpigmentation may persist at 
the initial places of EM lesions (7), as was the case in 
4 of our patients. Interestingly, in one of our patients 
with Sjögren’s syndrome, granuloma annulare lesions 
developed in the areas of original EM after antimicro-
bial treatment. We anticipate that granuloma annulare 
might be triggered by LB rather than caused by LB per 
se (28–30).
The recent study by Sjöwall et al. (31) shows that a 
decreased Th1-type inflammatory cytokine expression 
in the infected skin early during the infection associa-
tes with persisting symptoms after treatment (such as 
arthralgia and fatigue) in 7/85 Finnish SEM patients. 
This could be a sign of inefficient early immune re-
sponse and it is possible that some patients with auto-
immune diseases may present such a deficiency. This 
would explain our findings of persisting skin lesions in 
2 patients with autoimmune disease. 
The frequency of systemic symptoms among the pa-
tients with SEM or MEM (31%) was similar to results 
from other European studies (27–37%) (32–34). Due 
to individual patient-related aspects and concomitant 
medications, the recommended treatment scheme so-
metimes varied from the guideline recommendations. 
The high frequency of multiple antimicrobial regimens 
(37%) reflects the difficulty in implementing a new 
treat ment guideline into the healthcare system (Table V).
The prevalence of ticks carrying B. burgdorferi is 
increasing in several parts of Europe. Our retrospec-
tive analysis demonstrates that LB cannot be ruled 
out even if the patient does not recall a tick bite. This 
is in line with the observation of Stanek et al. (2) and 
other studies, which report a highly varying percentage 
(21–73%) of patients with EM recalling a tick bite (7, 
31–36). It is crucial to emphasize that SEM and MEM 
can have varying clinical appearances (Fig. 1) and that 
detailed diagnostic measures are needed. 
The limitations of our study are due mainly to its 
retrospective form. The frequency of the documentation 
of serological and clinical data (including photography) 
were not standardized in advance and therefore varied 
according to clinical practice of the various physicians. 
Furthermore, patients did not always remember the 
duration of the skin lesion(s). Finnish evidence-based 
guidelines for treatment of SEM and lymphocytoma 
are available, but there are no Finnish guidelines for 
treatment of MEM. Therefore, the treatment of MEM 
has been varying as listed in Table V. Antimicrobial 
treatments were prescribed independently also by se-
veral other physicians than dermatologists, prior to 
presentation in our department. In addition, subspecies 
of the causative agent (B. afzelii or B. garinii) were not 
analysed. 
We conclude that EM is commonly underdiagnosed 
even in endemic areas. The multifaceted appearance 
of both SEM and MEM, combined with the fact that 
most patients do not recall having a tick bite, can cause 
difficulties in diagnosing LB in primary healthcare. In 
addition, the high percentage of seronegativity at the 
initial stage may be misleading. In this Finnish cohort 
of highly selected patients with PCR-confirmed LB 
presenting with clinically atypical SEM or MEM, more 
than half of the patients were not diagnosed for LB be-
fore arrival to the Department of Dermatology. This is 
important, since LB should be treated early, and since 
inadequate antimicrobial treatment might initially cause 
an atypical clinical picture that makes diagnosis more 
difficult. MEM might appear more frequently in Europe 
(8) than previously thought. It is likely that LB will 
become endemic in several parts of the world, because 
of climate changes that are favourable for ticks and 
their host animals (37). Therefore, it is important that 
physicians are aware of tick-borne diseases. Prospective 
research should be performed in order to determine 
whether patients with pre-existing autoimmune diseases 
need different treatment for LB.
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